NCT04629547招募中2 期
Sleep Trial to Prevent Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Change from baseline in Amyloid-β accumulation measured by plasma pT217/T217 in participants treated with 20 mg suvorexant compared to placebo
研究概览
简要总结
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
详细描述
This study will investigate if long-term treatment with suvorexant will slow amyloid-β accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected by plasma pT217/T217.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female.
- •Any race or ethnicity.
- •Participants must be age ≥65 years and able to sign informed consent.
- •Global Clinical Dementia Rating (CDR)
- •Willing and able to undergo study procedures.
排除标准
- •History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
- •STOP-Bang score >6 for participants without PAP
- •Untreated OSA with AHI ≥15 on home sleep test
- •Treated sleep apnea with PAP non-compliance
- •PAP compliance is defined as >= 4 hours per night >70% of the nights
- •Plasma A-beta and tau test with a plasma p-tau 217% ≤ 1.19
- •Chronic kidney disease defined as patients with markers of kidney damage or eGFR of < 45 ml/min/1.73m
- •Hepatic impairment defined as AST and/or ALT > 2x upper limit of normal (normal limits AST: 11-47 IU/L, ALT: 6-53 IU/L).
- •HIV/AIDS.
- •History of substance abuse or alcohol abuse in the proceeding 6 months.
- •Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.
- •History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.
- •Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion:
- •Cardiovascular disease requiring medication except for controlled hypertension.
- •Pulmonary disease.
- •Type I diabetes.
- •Neurologic or psychiatric disorder requiring medication.
- •Tobacco use.
- •Use of sedating medications.
- •Use of medications that interact with suvorexant (if cannot be discontinued)
- •Abnormal safety labs
- •History of current suicidal ideations.
- •Currently pregnant or breast-feeding.
- •In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.
- •Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
- •Must not participate in another drug or device study prior to the end of this study participation.
- •Exclusion criteria for optional lumbar punctures
- •• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).
研究组 & 干预措施
Poor sleep control grop
Placebo Comparator
60 participants will be randomized to take placebo daily at h.s. for 18-24 months
干预措施: Placebo (Drug)
Poor sleep treatment group
Experimental
60 participants will be randomized to take suvorexant 20mg daily at h.s. for 18-24 months
干预措施: Suvorexant 20 mg (Drug)
结局指标
主要结局
Change from baseline in Amyloid-β accumulation measured by plasma pT217/T217 in participants treated with 20 mg suvorexant compared to placebo
时间窗: 18-24 months
Blood collection
次要结局
- Change in plasma Amyloid-β compared to placebo(18-24 months)
- Change in CSF Amyloid-β compared to placebo(18-24 months)
- Change in plasma tau compared to placebo(18-24 months)
- Change in CSF tau compared to placebo(18-24 months)
- Change in plasma p-tau compared to placebo(18-24 months)
- Change in CSF p-tau compared to placebo(18-24 months)
- Change in cognitive performance compared to placebo(18-24 months)
- Change in transcriptomics compared to placebo(18-24 months)
- Change in metabolomics compared to placebo(18-24 months)
- Change in proteomics compared to placebo(18-24 months)
- Change in gut microbiome compared to placebo(18-24 months)
研究者
Brendan Lucey
Principal Investigator, Sleep Medicine Section Head
Washington University School of Medicine
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Online COgnitive Behavioural Therapy for Sleep and Mental Health for Older Adults With Insomnia and Subjective Cognitive ComplaintsInsomniaNCT06032377Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal275
尚未招募
不适用
CPAP Randomized Controlled TrialObstructive Sleep Apnea (OSA)Mild Cognitive Impairment (MCI)Cognitive Decline Prevention in Pre-frail Older AdultsNCT06773416Sunnybrook Health Sciences Centre206
招募中
不适用
Combating Alzheimer's Through Sleep and ExerciseAlzheimer DiseaseDementiaNCT04855630University of Miami30
招募中
不适用
Sleep-dependent Learning in AgingSleepNCT03840083University of Massachusetts, Amherst584
已完成
不适用
Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)Acute Mountain SicknessNCT01842906Stanford University219